---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Effects on other drugs"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Effects on other drugs. Topics: In vitro inhibition of CYP2C8, CYP2C9, CYP2C19, and CYP2B6; In vitro CYP3A4 induction; In vitro inhibition of UGT isoforms and drug transporters; Simvastatin: clinical interaction study S337.1.002; 2 further topics. 6 evidence topics quoted from 2 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/effects-on-other-drugs"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Effects on other drugs

<a id="heading-2.1.2.9.2"></a>

## 2.1.2.9.2 Effects of Lanifibranor on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

### In vitro inhibition of CYP2C8, CYP2C9, CYP2C19, and CYP2B6

> “Lanifibranor was shown to be an inhibitor of CYP2C8 (IC50 4µM, Ki 8µM), CYP2C9 (IC50 8µM, Ki 21µM), CYP2C19 (IC50 25µM) and CYP2B6 (IC50 8µM).”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.9.2-2"></a>

### In vitro CYP3A4 induction

> “A limited risk of CYP induction could be expected in vivo, as only a slight CYP3A4 induction was observed at 20 µM of lanifibranor in one among all tested donors.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.9.2-3"></a>

### In vitro inhibition of UGT isoforms and drug transporters

> “Lanifibranor directly inhibited UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B7, UGT2B15 and UGT2B17 with IC50 values of 13, 26 to 38, 20, 83, 42, 33, 23 and 22 μM, respectively.”
> “Lanifibranor was shown to inhibit uptake and efflux transporters but with relatively high IC50 values: MDR1 (8.5 μM), BCRP (15.2 μM), BSEP (16.8 μM), OCT2 (267 μM), except for OATP1B1/3 (~1 µM).”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.9.2-4"></a>

### Simvastatin: clinical interaction study S337.1.002

> “The objectives of study S337.1.002 were to study the effect of lanifibranor on the pharmacokinetics of simvastatin and simvastatin acid and to evaluate the pharmacokinetics of the two crystalline anhydrous solid alpha and beta forms of lanifibranor.”
> “No significant drug-drug interaction was observed with Simvastatin (<2-fold), and no PK/genotype (CYP450 isoenzymes and UGTs isoform) relationship has been identified.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.9.2-5"></a>

### CYP2B6 and CYP2C8 substrates: excluded by protocol amendment

> “Clarification regarding prohibited medication: treatment with substrates of CYP2B6 and CYP2C8, CYP2C8 strong inducers and CYP2C8 strong inhibitors excluded.”
> “Prohibited medications listed in this protocol or that meet the criteria of a prohibited medication by class or substrate may not be used in this study.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-2.1.2.9.2-6"></a>

### Empagliflozin: combination assessed for interaction on glycemic control

> “Confirm a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control (i.e., conservation of the effect when associated with an SGLT2 inhibitor, no deleterious effect, no negative interaction on glycemic control), while assessing the safety and tolerability”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
